Welcome to the Xolair®
CSU website

Discover how Xolair® can make a difference to the lives of inadequately controlled chronic spontaneous urticaria (CSU) patients

Unmet need in CSU

Up to 50% of CSU patients have an inadequate response to H1-antihistamines at licenced doses1,2

Find out more

Treatment guidelines

International EAACI/GA2LEN/EDF/WAO guidelines recommend omalizumab as an add-on therapy for CSU patients with an inadequate response to H1-antihistamine treatment4

Find out more

Simple dosing schedule

Xolair® is administered by subcutaneous injection using a pre-filled syringe‡5

Find out more

Well tolerated

Xolair® was well tolerated in over 700 patients in the CSU phase III clinical program5

Find out more

Model is a hypothetical patient profile, for illustrative purposes only

*Data from ASTERIA II; two other Phase III studies (ASTERIA I and GLACIAL) were also conducted to assess the efficacy and safety of Xolair® in inadequately controlled CSU patients

†Xolair® 300 mg vs. baseline at 12 weeks; p<0.001 vs. placebo.

‡Xolair® is also available as a lyophilized formulation

References: 1. Maurer M, et al. N Engl J Med 2013;368:924-935. 2. Weller K, et al. J Eur Acad Dermatol Venereol 2013;27:43-50. 3. Maurer M, et al. N Engl J Med 2013;368:924-935. 4. Zuberbier T, et al. Allergy 2014;69:868-887. 5. Xolair® Summary of Product Characteristics 2016.

NP4 code: GLDEIM/IGE025E/0181

Terms of use - Privacy policy - About cookies - Cookie Settings - This site is intended for a global audience.

© 2017 Novartis Pharma